Smith & Nephew plc SNNUF Stock
Smith & Nephew plc Price Chart
Smith & Nephew plc SNNUF Financial and Trading Overview
| Smith & Nephew plc stock price | 14.91 USD |
| Previous Close | 14.91 USD |
| Open | 14.95 USD |
| Bid | 14.5 USD x 100000 |
| Ask | 16.45 USD x 10000 |
| Day's Range | 14.95 - 14.95 USD |
| 52 Week Range | 14.53 - 18.5 USD |
| Volume | 2K USD |
| Avg. Volume | 517 USD |
| Market Cap | 12.67B USD |
| Beta (5Y Monthly) | 0.672 |
| PE Ratio (TTM) | 20.708332 |
| EPS (TTM) | 0.72 USD |
| Forward Dividend & Yield | 0.39 (2.61%) |
| Ex-Dividend Date | March 26, 2026 |
| 1y Target Est | N/A |
SNNUF Valuation Measures
| Enterprise Value | 15.44B USD |
| Trailing P/E | 20.708332 |
| Forward P/E | 14.617647 |
| PEG Ratio (5 yr expected) | 1.21 |
| Price/Sales (ttm) | 2.055591 |
| Price/Book (mrq) | 2.3955655 |
| Enterprise Value/Revenue | 2.505 |
| Enterprise Value/EBITDA | 11.557 |
Trading Information
Smith & Nephew plc Stock Price History
| Beta (5Y Monthly) | 0.672 |
| 52-Week Change | -0.59% |
| S&P500 52-Week Change | 27.18% |
| 52 Week High | 18.5 USD |
| 52 Week Low | 14.53 USD |
| 50-Day Moving Average | 15.54 USD |
| 200-Day Moving Average | 16.52 USD |
SNNUF Share Statistics
| Avg. Volume (3 month) | 517 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 849.81M |
| Float | 839.53M |
| Short Ratio | N/A |
| % Held by Insiders | 0.22% |
| % Held by Institutions | 70.22% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.391 |
| Trailing Annual Dividend Yield | 2.62% |
| 5 Year Average Dividend Yield | 257.00% |
| Payout Ratio | 0.53209996 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 10.14% |
| Operating Margin (ttm) | 13.98% |
| Gross Margin | 68.25% |
| EBITDA Margin | 21.67% |
Management Effectiveness
| Return on Assets (ttm) | 5.26% |
| Return on Equity (ttm) | 11.84% |
Income Statement
| Revenue (ttm) | 6.16B USD |
| Revenue Per Share (ttm) | 7.11 USD |
| Quarterly Revenue Growth (yoy) | 7.39% |
| Gross Profit (ttm) | 4.21B USD |
| EBITDA | 1.34B USD |
| Net Income Avi to Common (ttm) | 625M USD |
| Diluted EPS (ttm) | 0.72 |
| Quarterly Earnings Growth (yoy) | 67.70% |
Balance Sheet
| Total Cash (mrq) | 557M USD |
| Total Cash Per Share (mrq) | 0.66 USD |
| Total Debt (mrq) | 3.33B USD |
| Total Debt/Equity (mrq) | 62.9 USD |
| Current Ratio (mrq) | 2.572 |
| Book Value Per Share (mrq) | 6.224 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 1.28B USD |
| Levered Free Cash Flow (ttm) | 876.63M USD |
Profile of Smith & Nephew plc
| Country | United States |
| State | N/A |
| City | Watford |
| Address | Building 5 |
| ZIP | WD18 8YE |
| Phone | 44 1923 477 100 |
| Website | https://www.smith-nephew.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 16988 |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Q&A For Smith & Nephew plc Stock
What is a current SNNUF stock price?
Smith & Nephew plc SNNUF stock price today per share is 14.91 USD.
How to purchase Smith & Nephew plc stock?
You can buy SNNUF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Smith & Nephew plc?
The stock symbol or ticker of Smith & Nephew plc is SNNUF.
Which industry does the Smith & Nephew plc company belong to?
The Smith & Nephew plc industry is Medical Devices.
How many shares does Smith & Nephew plc have in circulation?
The max supply of Smith & Nephew plc shares is 850.88M.
What is Smith & Nephew plc Price to Earnings Ratio (PE Ratio)?
Smith & Nephew plc PE Ratio is 20.70833200 now.
What was Smith & Nephew plc earnings per share over the trailing 12 months (TTM)?
Smith & Nephew plc EPS is 0.72 USD over the trailing 12 months.
Which sector does the Smith & Nephew plc company belong to?
The Smith & Nephew plc sector is Healthcare.


